EGFR and cholangiocarcinoma: Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been investigated in two distinct phase I trials involving patients with advanced CCA characterized by HER2 overexpression (NCT01935843) or EGFR overexpression (NCT01869166) [291,292].